ClinicalTrials.gg
RecruitingNCT06078384ETNAUpdated Jul 24, 2026

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

A Phase 2 interventional study of Pembrolizumab 25 mg/ml and Paclitaxel injection in Triple-negative Breast Cancer, sponsored by UNICANCER. Recruiting at 44 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by UNICANCER · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
354
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms — 17 open to participants now, 27 under way, 4 of them phase 3. pembrolizumab · Triple Negative Breast Neoplasms.

Planned enrollment
9th of 49
354 · median 52
Started
2024
with 7 others
Phase 2
33 of 49
13 open now
Primary completion
2032-01
later than 24 of 26 live
Registered
38th of 49
by date
Lead sponsor
2 of 49
UNICANCER

Among the 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms, this one is the 9th largest by planned enrollment, is one of 8 that started in 2024, is one of 33 in phase 2, reaches primary completion later than 24 of the 26 other live ones, and was the 38th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

17 of the 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

Triple-negative breast cancer (TNBC) is a group of tumors that occurs mainly in young, premenopausal women and accounts for 10-20% of breast cancers. Over the past decade, the incidence of women diagnosed with early-stage TNBC has significantly increased due to the widespread use of screening mammography. Treatment of patients with localized TNBC mainly involves surgery and (neo)adjuvant chemotherapy with or without radiotherapy. However, the benefit of chemotherapy may be controversial in patients with early-stage TNBC defined by small size and absence of lymph node involvement, and with significant tumor lymphocyte infiltration.

The ETNA study is a phase II trial designed to evaluate a chemotherapy de-escalation strategy in patients with TNBC T1b/c N0M0 and stromal TILs (sTILs) ≥ 30%. ETNA comprises two cohorts defined according to the level of TILs and the age of patients. Patients aged > 40 years with 30% ≤ sTILs \< 50% and those aged ≤ 40 years with 30% ≤ sTILs \< 75% will be included in the cohort 1 and will receive adjuvant pembrolizumab 200 mg every three weeks for 9 cycles and Paclitaxel 80 mg/m² weekly for 12 cycles. Patients aged > 40 years with sTILs ≥ 50% and those aged ≤ 40 years with sTILs ≥ 75% will be included in cohort 2 and will not receive adjuvant treatment, they will undergo standard surveillance every six months.

Read the detailed description

(Neo)adjuvant chemotherapy in breast cancer is associated to long-term persistent QoL deterioration in patients with early breast cancer, with a greater negative impact in patients that were premenopausal at diagnosis. Because triple negative breast cancer (TNBC), which accounts for 10-20% of breast cancers, presents a poorer prognosis as compared to the other subtypes, international guidelines endorse the use of adjuvant chemotherapy from TNBC tumors measuring > 5 mm. Nevertheless, a number of retrospective studies have reported excellent prognosis for patients with small, lymph node-negative and high TILs TNBC, even without chemotherapy, with 5-year overall survival (OS) of 98%. Findings from multiple data sets consistently demonstrated that TILs represent a robust prognostic and predictive biomarker in early-stage TNBC, being now the first biological prognostic marker for TNBC included in several international guidelines for early-stage disease, such as 2019 St Gallen consensus conference and European Society for Medical Oncology (ESMO) Guidelines for early-stage breast cancer.

In clinical practice, oncologists have taken different approaches in patients with stage I TNBC. While some have de-escalated anthracyclines, other did not held back on the standard chemotherapy options with anthracyclines, taxanes, and cyclophosphamide. Based on unpublished data from the TNBC pooled analysis with sTILs on 2211 patients not treated by systematic therapy, performed at Gustave Roussy, the 5-year distant disease free-survival (DDFS) is 87%, 91%, and 93% for those with stage I and sTILs ≥ 30%, 50%, and 75%, respectively. Given these compelling findings from historical observations, it is reasonable to anticipate that the absolute benefit of chemotherapy would be modest among these patients as their tumors generally exhibit a favorable prognosis, resulting in reduced benefits with the use of adjuvant chemotherapy.

ETNA is a phase II, multicenter, biomarker-driven study that is designed to characterize the clinical course of patients with stage I TNBC and sTILs ≥ 30%.

ETNA includes patients with stage I and sTILs ≥ 30% TNBC in 2 cohorts:

  • Cohort 1 will include patients age > 40 years with 30% ≤ sTILs \< 50% and those aged ≤ 40 years with 30% ≤ sTILs \< 75%. Patients will receive 9 cycles of adjuvant pembrolizumab 200 mg every three weeks for 9 cycles and Paclitaxel 80 mg/m² weekly for 12 cycles.
  • Cohort 2 will include patients aged > 40 years with sTILs ≥ 50% and those aged ≤ 40 years with sTILs ≥ 75% who will undergo standard surveillance (no adjuvant systemic treatments).
03

Conditions studied

  • Triple-negative Breast Cancer

Keywords

  • Breast cancer
  • De-escalation
  • Immunotherapy
  • Chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand, sign, and date the written form prior to any protocol- specific procedures performed,
  2. Men and women aged ≥ 18 years,
  3. (ECOG) performance status of 0 or 1,
  4. confirmed and radically removed pT1b/c N0M0 TNBC as defined according to AJCC TNM stage-8th version,

    • Histologically documented TNBC (negative , ER, and PgR status). HER2 negativity is defined by local laboratory assessment using in situ hybridization and immunohistochemistry assays as per ASCO/CAP criteria and ER/PgR negativity is defined by local laboratory assessment \< 10% using immunohistochemistry assays,
    • Bilateral and/or multifocal primary tumor is allowed and the tumor with the most advanced T stage should be used to asses for eligibility. If multifocal tumor, a pathologic confirmation of TNBC is required for each focus,
  5. Adequately excised breast cancer: subjects must have undergone either breast- conserving surgery or mastectomy/nipple- or skin-sparing mastectomy.

    • For subjects who undergo breast-conserving surgery, the margins of the resected specimen must be histologically free of invasive tumor and ductal carcinoma in situ (DCIS) as determined by the local pathologist. Reresections to ensure no ink on tumor margins are allowed. Subjects with margins positive for lobular carcinoma in situ (LCIS) are eligible without additional resection.
    • For subjects who undergo mastectomy/nipple- or skin-sparing mastectomy, margins must be free of gross residual tumor. It is recommended that subjects should have a negative microscopic margin in accordance with local pathology protocol,
  6. Have had sentinel lymph node (SLNB) and/or axillary lymph node dissection (ALND) for evaluation of pathologic nodal status.

    Axillary nodal dissection(s) should yield a total of at least six nodes (including the axillary lymph nodes resected at the SLNB plus the lymph nodes collected at the axillary nodal dissection),

  7. At least 4 weeks but no more than 12 weeks between definitive breast surgery (or the last surgery with curative intent if additional resection is required for breast cancer) and treatment initiation for cohort 1 and no more than 12 weeks for cohort 2,
  8. Centrally assessed TILs score from surgical formalin-fixed paraffin embedded (FFPE) tumor sample, using an H\&E stained diagnostic digital slide, according to the most recent International TILs Working Group guidelines,

    • Cohort 1 will include patients aged > 40 years with 30% ≤ sTILs \< 50% and those aged

      • 40 years with 30% ≤ sTILs \< 75%
    • Cohort 2 will include patients aged > 40 years with sTILs ≥ 50% and those aged ≤ 40 years with sTILs ≥ 75%
  9. Women of have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study medication for cohort 1 and within 7 days of inclusion for cohort 2,
  10. Women of childbearing potential must agree to use protocol-specified method(s) of for 3 years after patient inclusion. Men subjects who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception during trial treatments and for at least 6 months after the last dose of trial treatments.

    Females of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year,

  11. Patients affiliated to the social security system (or equivalent)- France only,
  12. Patient is willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up.

    Additional inclusion criteria for subjects of cohort 1:

  13. (LVEF) of ≥ 50% as assessed by echocardiogram or cardiac scintigraphy,
  14. Demonstrate adequate organ function within 7 days of inclusion

    • (ANC) ≥ 1,500 /µL
    • ≥ 100,000 /µL
    • ≥ 9 g/dL
    • ≥ 30 mL/min for subject with creatinine levels > 1.5 x institutional (ULN)
    • Total ≤ 1.5 x ULN or direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN
    • (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN
    • Albumin ≥ 3.0 g/dL
    • Lactate dehydrogenase (LDH) \< 2.5 X ULN
    • /partial thromboplastin time (INR/PTT) ≤ 1.5 x ULN (unless subject is receiving anticoagulant therapy as long as prothrombin time (PT) or PTT is within therapeutic range of intended use of anticoagulants)
    • Thyroid stimulating hormone (TSH), free T4 (FT4), and free T3 (FT3) within normal ranges
    • Cortisol at 8 AM within normal ranges
    • Lipase and amylase \< 3 ULN
    • Fasting plasma glucose ≤ 120 mg/dl or 6.7 mmol/L
    • Troponin within normal range

Exclusion criteria

Exclusion Criteria:

  1. History of invasive ≤ 3 years prior to signing except for adequately treated basal cell or squamous cell skin cancer,
  2. Having received prior chemotherapy or targeted therapy within the past 12 months,
  3. Has a prior history of DCIS and/or LCIS that was treated with any form of systemic, hormonal therapy, or radiotherapy to the ipsilateral breast; subjects who had their DCIS/LCIS treated only with surgery and/or contralateral DCIS treated with radiotherapy are allowed to enter the study,
  4. Having received prior therapy with an , anti-PD-L1, or anti-PD-L2 agents or with an agent directed to another co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137),
  5. Treatment with systemic immunostimulatory agents (including, but not limited to, interferons, interleukin-2) within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to inclusion,
  6. Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of medications (including prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] alpha agents) within 7 days prior to inclusion:

    • Subjects who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in the study
    • The use of inhaled corticosteroids and mineralocorticoids is allowed,
  7. Has an active disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment; subjects with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only are eligible if:

    • Rash must covers \<10% of body surface area.
    • Disease is well controlled at baseline and requires only low-potency topical Corticosteroids and no acute exacerbations requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or oral corticosteroids occurred within the previous 12 months,
  8. Has a known history of (HIV),
  9. Prior allogeneic stem cell or solid organ transplant,
  10. Has a known history of active Bacillus Tuberculosis,
  11. Patients with any other disease or illness which requires hospitalisation or is incompatible with the trial treatment are not eligible,
  12. Pregnant women or breastfeeding or expecting to conceive within the projected duration of the study, from the inclusion visit until the end of the 3 years follow up. Men subjects who engage in heterosexual intercourse and refuse to use protocol-specified method(s) of during trial treatments and for at least 6 months after the last dose of trial treatments,
  13. Patients unable to comply with trial obligations for geographic, social, or physical reasons, or who are unable to understand the purpose and procedures of the trial,
  14. Person deprived of their liberty or under protective custody or guardianship,
  15. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

    Additional non-inclusion criteria for subjects of cohort 1:

  16. Has cardiac dysfunction as defined by any of the following prior to inclusion:

    • History of v5.0 Grade > 3 symptomatic congestive heart failure or (NYHA) criteria Class II,
    • Angina pectoris requiring anti-anginal medication, serious cardiac arrhythmia not controlled by adequate medication, severe conduction abnormality, or valvular disease,
    • Significant symptoms (≥ Grade 2) relating to left ventricular dysfunction or cardiac ischemia,
  17. Has a known (≥ Grade 3) to the components of the study therapy or its analogs,
  18. Has received a or live-attenuated vaccine within 30 days of the first dose of study treatment,
  19. Concurrent active virus (HBV; defined as HBsAg positive and/or detectable HBV DNA) and virus (HCV; defined as anti-HCV Ab positive and detectable HCV RNA) infection,
  20. Severe infections within 4 weeks prior to initiation of study treatment, including, hospitalization for complications of infection, bacteremia, or severe pneumonia,
  21. Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment; subjects receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection) are eligible,
  22. Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment or anticipation of need for a major surgical procedure during study treatment,
  23. Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has a current pneumonitis/interstitial lung disease,
  24. Is currently participating in or has participated in an interventional clinical trial with an compound or device within 4 weeks of the first dose of treatment in this current trial.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
354 participants (estimated)

Study arms

  • Experimental
    Cohort 1-Pembrolizumab plus Paclitaxel

    Pembrolizumab will be administered at a fixed dose of 200 mg every 3 weeks (Q3W), with a total of 9 cycles and Paclitaxel 80 mg/m² weekly for 12 cycles

    Drug: Pembrolizumab 25 mg/ml · Drug: Paclitaxel injection

  • No intervention
    Cohort 2-Observation

    No treatment will be administered, patients will undergo standard surveillance every 6 months according to local practice.

Interventions

  • DrugPembrolizumab 25 mg/ml

    Drug page: PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pembrolizumab drug product is a sterile-filtered liquid and is aseptically filled into single-use vials. The vials contain 4 mL of sterile solution for IV infusion.

    Also known as: keytruda

  • DrugPaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Injectable solution for IV administration. Dose of 80 mg/m² weekly.

    Also known as: Taxol

06

What researchers measure

Primary outcomes

  1. Distant disease-free survival (DDFS)

    Distant disease-free survival is defined as the delay between date of inclusion and distant tumor relapse, second cancer, or death from any cause, whichever occurs first.

    Time frame: 5 year

Secondary outcomes

  1. Invasive disease-free survival (IDFS)

    Invasive disease-free survival is defined as the delay between date of inclusion and invasive breast tumor recurrence, distant recurrence, second cancer, or death from any cause, whichever occurs first.

    Time frame: From inclusion up to 5 year

  2. Distant recurrence-free survival (DRFS)

    Distant recurrence-free survival is defined as the delay between date of inclusion and distant recurrence of breast cancer or death from any cause, whichever occurs first.

    Time frame: From inclusion up to 5 year

  3. Overall survival (OS)

    The overall survival is the length of time from inclusion that patients enrolled in the study are still alive.

    Time frame: From inclusion to death from any cause, up to 5 year

  4. Incidence of Adverse Events

    The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders.

    Time frame: Throughout study completion, up to 5 year

  5. Quality of life questionnaire - Core 30 (QLQ-C30)

    Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials. The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At baseline, every 3 weeks for 6 months then every 6 months up to 5 years

  6. Quality of Life Questionnaire - Breast cancer module (QLQ-BR23)

    This EORTC breast cancer specific questionnaire is intended to supplement the QLQ-C30. The QLQ-BR23 contains 23 items incorporating five multi-item scales to assess systemic therapy side effects, arm symptoms, breast symptoms, body image and sexual functioning. In addition, single items assess sexual enjoyment, hair loss and future perspective. All items are rated on a four-point Likert-type scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), and are linearly transformed to a 0-100 scale. For all items but sexual functioning and sexual enjoyment, higher scores indicate more severe symptoms.

    Time frame: At baseline, every 3 weeks for 6 months then every 6 months up to 5 years

  7. Quality of Life Questionnaire - Cancer-related fatigue (QLQ-FA12)

    This EORTC cancer related fatigue questionnaire is intended to supplement the QLQ-C30. The QLQ-FA12 contains 12 items organized in three subscales: physical fatigue (5 items), emotional fatigue (3 items), and cognitive fatigue (2 items). The remaining two items serve as global indicators for interference of fatigue with daily activities and social sequelae of fatigue. All items are rated on a four-point Likert-type scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), and are linearly transformed to a 0-100 scale with higher scores indicating greater degree of fatigue.

    Time frame: At baseline, every 3 weeks for 6 months then every 6 months up to 5 years

  8. Hospital anxiety and depression scale (HADS)

    The HADS is a 14 items questionnaire: 7 items related to anxiety and 7 items related to depression scored on a scale. Scores for items in each subscale of the HADS are summed to produce an anxiety score (HADS-A) or a depression score (HADS-D), or can be added to produce a total score corresponding to emotional distress (HADS-T). Each item is rated on a 4-point Likert scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), for a total score ranging from 0-21 for each subscale. The entire scale (emotional distress) range from 0 to 42, with higher scores indicating more distress.

    Time frame: At baseline, every 3 weeks for 6 months then every 6 months up to 5 years

07

Study locations

25 of 44 sites recruiting
  • CHU Amiens Picardie_Site Sud
    Amiens, 80054, France
    Recruiting
    • Aurélie MOREIRA, MD · Contact
    • Aurélie MOREIRA, MD · Principal investigator
  • Institut Sainte Catherine
    Avignon, 84918, France
    Recruiting
    • Julien GRENIER · Contact
    • Julien GRENIER, MD · Principal investigator
  • Centre Hospitalier de la Côte Basque
    Bayonne, 64109, France
    Recruiting
    • Thomas GRELLETY, MD · Contact
    • Thomas GRELLETY, MD · Principal investigator
  • Institut Bergonié
    Bordeaux, 33000, France
    Not yet recruiting
    • Maxime BRUNET, MD · Contact
    • Maxime BRUNET, MD · Principal investigator
  • Polyclinique Bordeaux Nord Aquitaine
    Bordeaux, 33077, France
    Recruiting
    • Nadine DOHOLLOU, MD · Contact
    • Nadine DOHOLLOU, MD · Principal investigator
  • Centre François Baclesse
    Caen, 14000, France
    Recruiting
    • George EMILE, MD · Contact
    • George EMILE, MD · Principal investigator
  • Pôle Santé Republique
    Clermont-Ferrand, 63000, France
    Recruiting
    • Lionel Moreau, MD · Contact
    • Lionel MOREAU, MD · Principal investigator
  • Centre Jean Perrin
    Clermont-Ferrand, 63011, France
    Recruiting
    • Marie-Ange MOURET-REYNIER, MD · Contact
    • Marie-Ange MOURET-REYNIER, MD · Principal investigator
  • Centre Georges-François Leclerc
    Dijon, 21000, France
    Not yet recruiting
    • Isabelle DESMOULINS · Contact
    • Isabelle DESMOULINS · Principal investigator
  • Hôpital Franco-Britannique-Fondation Cognacq-Jay
    Levallois-Perret, 92300, France
    Not yet recruiting
    • Nathalie PEREZ-STAUB, MD · Contact
    • Nathalie PEREZ-STAUB, MD · Principal investigator
  • CHU de Limoges
    Limoges, 87042, France
    Recruiting
    • Elise DELUCHE, MD · Contact
    • Elise DELUCHE, MD · Principal investigator
  • Centre Léon Bérard
    Lyon, 69008, France
    Recruiting
    • Olivier TREDAN, MD · Contact
    • Olivier TREDAN, MD · Principal investigator
  • Hopital Privé Jean Mermoz
    Lyon, 69008, France
    Recruiting
    • Olfa DERBEL, MD · Contact
    • Olfa DERBEL, MD · Principal investigator
  • Institut Paoli-Calmettes
    Marseille, 13009, France
    Recruiting
    • Frédéric VIRET, MD · Contact
    • Frédéric VIRET, MD · Principal investigator
  • Institut régional du Cancer de Montpellier
    Montpellier, 34298, France
    Not yet recruiting
    • Véronique D'HONDT, MD · Contact
    • Véronique D'HONDT, MD · Principal investigator
  • Hôpital privé du confluent
    Nantes, 44200, France
    Recruiting
    • Dorothée CHOCTEAU-BOUJU, MD · Contact
    • Dorothée CHOCTEAU-BOUJU, MD · Principal investigator
  • Centre Antoine Lacassagne
    Nice, 61000, France
    Recruiting
    • Jean-Marc FERRERO · Contact
    • Jean-Marc FERRERO · Principal investigator
  • CHU de Nîmes
    Nîmes, 30029, France
    Recruiting
    • Frédéric FITENI, MD · Contact
    • Frédéric FITENI, MD · Principal investigator
  • Centre Hospitalier de Pau
    Pau, 64046, France
    Recruiting
    • Kévin BOURCIER, MD · Contact
    • Kévin BOURCIER, MD · Principal investigator
  • Hôpital Privé des côtes d'Armor
    Plérin, 22190, France
    Not yet recruiting
    • Jérôme MARTIN-BABAU, MD · Contact
    • Jérôme MARTIN-BABAU, MD · Principal investigator
  • Hôpital NOVO
    Pontoise, 95300, France
    Recruiting
    • Rolande NGUEFACK · Contact
    • Rolande NGUEFACK, MD · Principal investigator
  • Centre Hospitalier de Cornouaille
    Quimper, 29107, France
    Recruiting
    • Mathilde BUREAU · Contact
    • Mathilde BUREAU, MD · Principal investigator
  • Clinique La Croix du Sud
    Quint-Fonsegrives, 31130, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Institut Godinot
    Reims, 51100, France
    Recruiting
    • Christelle JOUANNAUD, MD · Contact
    • Christelle JOUANNAUD, MD · Principal investigator
  • Centre Eugène Marquis
    Rennes, 35000, France
    Recruiting
    • Fanny LE DU, MD · Contact
    • Fanny LE DU, MD · Principal investigator
  • CHU de Saint Etienne
    Saint-Etienne, 42055, France
    Recruiting
    • Alicia QUILEZ-CUTILLAS, MD · Contact
    • Alicia QUILEZ-CUTILLAS, MD · Principal investigator
  • Institut Claudius Regaud
    Toulouse, 31059, France
    Recruiting
    • Florence DALENC, MD · Contact
    • Florence DALENC · Principal investigator
  • CHU Bretonneau
    Tours, 37000, France
    Recruiting
    • Marie-Agnès BY, MD · Contact
    • Marie-Agnès BY, MD · Principal investigator
  • Centre Alexis Vautrin
    Vandœuvre-lès-Nancy, 54519, France
    Recruiting
    • Anne KIEFFER, MD · Contact
    • Anne KIEFFER, MD · Principal investigator
  • Gustave Roussy
    Villejuif, 94805, France
    Recruiting
    • Elie Rassy, MD · Contact
    • Elie Rassy, MD · Principal investigator
  • Hospital General Universitario Dr.Balmis
    Alicante, Spain
    Not yet recruiting
  • Ico Badalona
    Badalona, 08916, Spain
    Not yet recruiting
    • Margeli VILA · Contact
    • Margeli VILA, MD · Principal investigator
  • Hospital Vall D'Hebrón
    Barcelona, 08035, Spain
    Not yet recruiting
    • Mafalda OLIVEIRA, MD · Contact
    • Mafalda OLIVEIRA, MD · Principal investigator
  • Hospital Clinico Universitario Virgen de La Arrixaca
    El Palmar, 30120, Spain
    Not yet recruiting
    • Pilar SANCHEZ HENAREJOS, MD · Contact
    • Pilar SANCHEZ HENAREJOS, MD · Principal investigator
  • Hospital Universitario Clinico San Cecilio
    Granada, 18016, Spain
    Not yet recruiting
    • Maria Isabel BLANCAS, MD · Contact
    • Maria Isabel BLANCAS, MD · Principal investigator
  • Ico Hospitalet
    L'Hospitalet de Llobregat, 08908, Spain
    Recruiting
    • Sonia PERNAS, MD · Contact
    • Sonia PERNAS, MD · Principal investigator
  • Complejo Asistencial Universitario de Leon
    León, 24071, Spain
    Not yet recruiting
    • Maria MARTINEZ GARCIA, MD · Contact
    • Maria MARTINEZ GARCIA, MD · Principal investigator
  • Hu Arnau de Vilanova Lleida
    Lleida, 25198, Spain
    Not yet recruiting
    • Serafin MORALES · Contact
    • Serafin MORALES, MD · Principal investigator
  • Hospital Ramon Y Cajal
    Madrid, 28034, Spain
    Not yet recruiting
    • Elena LÓPEZ FLORES · Contact
    • Elena LÓPEZ FLORES, MD · Principal investigator
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
    Not yet recruiting
    • Manuel ALVA BIANCHI, MD · Contact
    • Manuel ALVA BIANCHI, MD · Principal investigator
  • Hospital Universitari Son Espases
    Palma de Mallorca, 07120, Spain
    Not yet recruiting
    • Antonia PERELLÓ, MD · Contact
    • Antonia PERELLÓ, MD · Principal investigator
  • Hospital Sant Joan de Reus
    Reus, 43204, Spain
    Not yet recruiting
    • Alba COCHS · Contact
    • Alba COCHS, MD · Principal investigator
  • Hospital Universitario Virgen Del Rocio
    Seville, 41013, Spain
    Not yet recruiting
    • Monica CEJUELA · Contact
    • Monica CEJUELA, MD · Principal investigator
  • Hospital Clínico Valencia
    Valencia, 46010, Spain
    Not yet recruiting
    • Juan Miguel CEJALVO · Contact
    • Juan Miguel CEJALVO, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jan 2032, 84 months after the start.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 84 months is above that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2023
First posted
Oct 11, 2023
StartActual
Dec 27, 2024
Primary completionEst.
Jan 1, 2032
CompletionEst.
Jan 1, 2032
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06078384
Lead sponsor
UNICANCER
Collaborators
MSD France, SOLTI Breast Cancer Research Group, Gustave Roussy, Cancer Campus, Grand Paris, Vall Hebron Insitut Recerca
Responsible party
Sponsor
First posted
Oct 11, 2023
Start date
Dec 27, 2024
Primary completion
Jan 1, 2032 (estimated)
Completion
Jan 1, 2032 (estimated)
Last update
Jul 24, 2026

Study contacts

Telma ROQUE, PhD
Contact
etna@unicancer.fr
+33 (0) 1 80 50 12 92
Sylvie Mijonnet
Contact
s-mijonnet@unicancer.fr
Elie Rassy, MD
principal investigator · Gustave Roussy, Villejuif, France
Barbara Pistilli, MD
principal investigator · Gustave Roussy, Villejuif, France
Mafalda Oliveira, MD
principal investigator · HOSPITAL VALL D'HEBRÓN, Barcelona, Spain

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pembrolizumab · Paclitaxel

Start the discussion